Moreover, dual anti-ActRIIA/IIB antibody treatment reduced serum levels of IL-6 and reversed cachexia in mice, supporting a functional link between activin A and IL-6 signaling pathways observed in ovarian cancer cells [75]. This evidence concerns the gene IL6 and ovarian cancer.